Primary central nervous system lymphomas

被引：25
作者：
DeAngelis L.M. [1 ]
机构：
[1] Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, 10021-6700, NY
来源：
Current Treatment Options in Oncology | 2001年 / 2卷 / 4期
关键词：
Main Drug Interaction; Main Side Effect; Ommaya Reservoir; Primary Central Nervous System Lymphoma; Primary Central Nervous System Lymphoma Patient;
D O I：
10.1007/s11864-001-0024-6
中图分类号：
学科分类号：
摘要：
Primary central nervous system lymphoma (PCNSL) is widely regarded as one of the primary brain tumors most amenable to treatment. Although whole brain radiotherapy was the cornerstone of therapy for decades, recent work clearly indicates that chemotherapy has become the primary focus of treatment for this disease. The initial treatment of PCNSL for all patients, including the elderly, should be chemotherapy using a high-dose methotrexate-based regimen. Although cranial irradiation has often been combined with methotrexate, the unacceptably high incidence of late neurotoxicity, particularly in older patients, has caused many to eliminate radiotherapy, especially in those older than age 60 years. Emerging data support the validity of this approach, and the development of more efficacious chemotherapeutic regimens has been the focus of recent research. © 2001, Current Science Inc.
引用
收藏
页码：309 / 318
页数：9
相关论文
共 18 条
  • [1] DeAngelis L.M., Yahalom J., Primary central nervous system lymphoma, Principles and Practice of Oncology Updates, 6, pp. 1-12, (1992)
  • [2] Glantz M.J., Cole B.F., Friedberg M.H., Et al., A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors, Neurology, 46, pp. 985-991, (1996)
  • [3] Weaver S., Forsyth P., Fulton D., Et al., A prospective randomized study of prophylactic anticonvulsants (AC) in patients with primary brain tumors (PBT) or metastatic brain tumors (MBT) and without prior seizures (Sz): a preliminary analysis of 67 patients [abstract], Neurology, 45, (1995)
  • [4] Ferreri A.J.M., Reni M., Villa E., Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials, Ann Oncol, 11, pp. 927-937, (2000)
  • [5] Reni M., Ferreri A.J.M., Garancini M.P., Et al., Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature, Ann Oncol, 8, pp. 227-234, (1997)
  • [6] Abrey L.A., DeAngelis L.M., Yahalom J., Long-term survival in primary CNS lymphoma, J Clin Oncol, 16, pp. 859-863, (1998)
  • [7] Abrey L.E., Yahalom J., DeAngelis L.M., Treatment for primary central nervous system lymphoma (PCNSL): the next step, J Clin Oncol, 18, pp. 3144-3150, (2000)
  • [8] McAllister L.D., Doolittle N.D., Guastadisegni P.E., Et al., Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma, Neurosurgery, 46, pp. 51-60, (2000)
  • [9] O'Neill B.P., O'Fallon J.R., Earle J.D., Et al., Primary central nervous system non-Hodgkin’s lymphoma: survival advantages with combined initial therapy, Int J Radiat Oncology Biol Phys, 33, pp. 663-673, (1995)
  • [10] Mead G.M., Bleehen N.M., Gregor A., Et al., A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma. Cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, Cancer, 89, pp. 1359-1370, (2000)
12